ArticleMethods in molecular biology (Clifton, N.J.)2026
GeoMx Spatial Transcriptomics for Comprehensive Glioblastoma Molecular Profiling.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) remains one of the most aggressive and heterogeneous brain tumors, with a high degree of molecular complexity that challenges both diagnosis and treatment. To address these challenges, this chapter details a methodology that utilizes the GeoMx Digital Spatial Profiler (GeoMx DSP, NanoString Technologies, Bruker) for comprehensive molecular profiling of GBM. The chapter outlines the application of GeoMx DSP in combination with the manufacturer's Whole Transcriptome Atlas (WTA) and Next-Generation Sequencing (NGS), enabling spatially resolved transcriptomic analysis within preserved tissue architecture. This integrated approach allows for detailed characterization of the molecular landscape in GBM at both spatial and transcriptional levels, facilitating the discovery of tumor microenvironment interactions, cellular heterogeneity, and potential therapeutic targets, thus advancing GBM research and clinical applications by supporting personalized treatment development.
Indexed as
Identifiers
42681467What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.